Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 11/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.32 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19687131 | 0.87 | IDH1 (0.38) | IDH1HRH4IDH2 | |
| SCHEMBL19687081 | 0.86 | IDH1 (0.37) | IDH1IDH2IRAK4 | |
| SCHEMBL19686471 | 0.86 | IDH1 (0.44) | IDH1HRH4IDH2 | |
| SCHEMBL19686475 | 0.86 | IDH1 (0.41) | IDH1HRH4IDH2PRKD1PRKD2 | |
| SCHEMBL19686472 | 0.85 | IDH1 (0.44) | IDH1HRH4IDH2 | |
| SCHEMBL19686476 | 0.84 | CHRM3 (0.46) | IDH1HRH4IDH2 | |
| SCHEMBL19686478 | 0.83 | HRH4 (0.47) | IDH1HRH4IDH2PRKD1PRKD2 | |
| SCHEMBL19686469 | 0.83 | IDH1 (0.40) | IDH1IDH2 | |
| SCHEMBL19687010 | 0.83 | IDH1 (0.40) | IDH1HRH4IDH2 | |
| SCHEMBL19686480 | 0.83 | IDH1 (0.42) | IDH1HRH4IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885PTGER4 1339/4885HRH4 2164/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885PTGER4 1339/4885HRH4 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.